PharmaCielo Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marc Lustig
- Full Time Employees
- 268
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 82 Richmond Street East Toronto ON Canada M5C 1P1
- IPO Date
- Jan 25, 2019
- Website
- pharmacielo.com
- Similar Companies
- Business
- PharmaCielo Ltd. and its affiliated entities specialize in the cultivation, rigorous processing, and global distribution of medical-grade cannabis products. The company focuses on producing high-purity cannabinoid extracts, including a diverse range of oils, distillates, and isolates for both CBD-dominant and THC-dominant applications, alongside dried cannabis flower. Beyond its core offerings, it provides white-label services for third-party brands and offers a telemedicine platform. PharmaCielo primarily serves health and wellness manufacturers, pharmaceutical companies, medical clinics, and cosmetic brands across international markets, including North America, Europe, and Latin America. Leveraging a vertically integrated model from Colombia, the company emphasizes sustainable cultivation and EU GMP-compliant production standards. Recent strategic initiatives include a partnership with Benuvia Operations for pharmaceutical-grade CBD API manufacturing and a supply agreement with Ease Labs for the São Paulo government in Brazil. PharmaCielo Ltd. maintains its corporate headquarters in Toronto, Canada.
PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge Financing
PharmaCielo Announces Intention to Issue Interest Shares
PharmaCielo Announces the Issuance of Interest Shares
PharmaCielo Announces 2025 Q3 Results, AGM Details
PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares
PharmaCielo Announces Revocation of FFCTO and Related Corporate Matters
PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes Audit
PharmaCielo Announces Issuance of Cease Trade Order
PharmaCielo Reports Q4 2024 Financial Results
PharmaCielo Announces Issuance of Shares for Settlement of Certain Amounts Owing
PharmaCielo Reports Q3 2024 Financial Results
PharmaCielo Announces Intention to Extend Expiry Date of Warrants
PharmaCielo Announces Change to Financial Year-End, and Appointment of Davidson & Company LLP as Auditor Effective October 7, 2024
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2024
CORRECTION FROM SOURCE: PharmaCielo Provides Update on Reinstatement for Trading
PharmaCielo Provides Update on Reinstatement for Trading
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023, and the First Quarter Ended March 31, 2024
PharmaCielo Announces Issuance of Failure to File Cease Trade Order
PharmaCielo Signs Binding Letter of Intent to Acquire Operations in Thailand; Announces $2 Million Non-Brokered Private Placement with Participation from PharmaCielo Insiders and Siam Ventures Investors
PharmaCielo to Supply Ease Labs with Commercial Shipments of API to Fulfill Contract with State Government of Sao Paulo, Brazil